Louis W. Beardell, Jr.

Louis counsels on all matters related to patent strategies, patent validity, patent due diligence, and freedom-to-operate opinions. His clients include an array of US and international companies in pharmaceuticals, chemicals, biotechnology, agricultural science, medical devices, and food science as well as major venture capital funds.

As companies evolve and modernize the way they operate, Louis ensures that they are able to establish exclusive positions to protect how they do business through procuring business method patents, as well as evaluating patent validity and freedom-to-operate positions for computer and business method inventions. His ability to prosecute patents and handle important trade secrets allows him to counsel clients through the creation of a diverse assortment of IP programs.

Louis frequently lectures to academic institutions and professional organizations on a variety of IP topics. He has been hosted by US and international IP and business associations, as well as top law schools and business school IP and entrepreneur classes.

• Acerta Pharma B.V. in implementation of IP program and in its acquisition by AstraZeneca
• Established and implemented intellectual property programs for many small, midsize, and multinational companies in the life sciences, technology and financial services sectors.
• OncoEthix SA in implementation of IP program and in its acquisition by Merck.
• Foresight Biotherapeutics, Inc. in implementation of an IP program, and acquisition of Foresight by Shire.
• Chiesi Farmaceutici SpA in its acquisition of all outstanding shares of Cornerstone Therapeutics Inc., valuing Cornerstone at about $255 million.
• Piper Jaffray & Co. and Leerink Swann LLC in the $30 million IPO of Tengion, Inc.
• Smiths Interconnect, a division of firm client Smiths Group plc, in its purchase of Interconnect Devices Inc. from an investor group led by private equity firm Milestone Partners for approximately $185 million.
• Roquette Freres v. SPI Pharma in support of successful defense of SPI Pharma in patent litigation matter.
• Kraft Foods in its sale of its Balance Bar Company to private equity firm Brynwood Partners.
• K-Tron International, Inc. in its sale to Hillenbrand, Inc. for $150 per share in cash, resulting in an aggregate purchase price of $435 million.
• LEO Pharma in its reacquisition of Warner Chilcott's exclusive product licensing rights in the United States, as well as rights to all products in LEO Pharma's development pipeline.
• Adolor Corporation in connection with its exclusive worldwide collaboration with Pfizer.
• Enzon, Inc. in its acquisition of the North American rights to Abelcet, an antifungal used to treat patients with invasive fungal infections related to cancer, organ transplantation and other conditions.
• Sekisui Chemical Company,a subsidiary of Sekisui America Corporation, in the $25.5 million purchase of American Diagnostica Inc.
• ViroPharma in its global collaboration and licensing agreement for the subcutaneous combination of Cinryze® (C1 esterase inhibitor [human]) with Halozyme Therapeutics' recombinant human hyaluronidase enzyme (rHuPH20) EnhanzeTM technology.
• GSI Commerce in its $2.4 billion acquisition by eBay.